Mereo BioPharma MREO 深 沪
已收盘 10-30 16:00:00 美东时间
0.2895
-0.012
-4.08%
华盛通- 最 高0.315
- 今 开0.2967
- 成交量 54.37万股
- 最 低 0.28
- 昨 收 0.3018
- 总市值 4623.05万
- 52周最高 2.37
- 市盈率 静 --
- 换手率 0.34%
- 52周最低 0.20
- 委 比 0.00%
- 总股本 1.60亿
- 历史最高 17.62
- 量 比 1.14
- 振 幅 11.60%
- 历史最低 0.20
- 每 手 1
- 风险率 0.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Diagonal Therapeutics Appoints Industry Veteran Jeremy Bender, Ph.D., M.B.A., as Chair of the Board of Directors
Diagonal Therapeutics appoints Jeremy Bender, Ph.D., M.B.A., as Board Chair, bringing over 20 years of biotech leadership and drug development experience. The company is advancing DIAG723, a multispecific clustering antibody targeting hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH), currently in a Phase 1/2 clinical trial. Bender's expertise will support the company's pipeline progress and strategic growth.
10-29 12:00
Mereo Biopharma Group Plc收跌1.98%，成交额14.62万美元
10月24日，Mereo Biopharma Group Plc（MREO）收跌1.98%，报0.28美元，成交额14.62万美元，市值4498.48万美元。...
10-24 07:29
Mereo Biopharma Group Plc收跌1.97%，成交额21.69万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:29
JP Morgan Downgrades Mereo BioPharma Group to Underweight
JP Morgan analyst Priyanka Grover downgrades Mereo BioPharma Group (NASDAQ:MREO) from Neutral to Underweight.
08-19 20:39
Mereo BioPharma Group Q2 EPS $(0.01), Inline
Mereo BioPharma Group (NASDAQ:MREO) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.02) per share from the same period last year.
08-11 20:17
Mereo BioPharma Group shares are trading higher after the company announced an optional and license agreement with Zydus Unit Sentynl For U.S. commercial and global manufacturing rights to alvelestat for AATD-LD.
Mereo BioPharma Group shares are trading higher after the company announced an optional and license agreement with Zydus Unit Sentynl For U.S. commercial and global manufacturing rights to alvelestat for AATD-LD.
08-11 20:09
Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
Mereo BioPharma and Sentynl Therapeutics have entered into an agreement for the U.S. commercial and global manufacturing rights to alvelestat, a potential first-in-class oral treatment for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD). Sentynl will have the right to commercialize the product in the United States, while Mereo retains global development leadership and rest-of-the-world rights. Mereo will receive upfront payments,...
08-11 12:00
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
Aura Biosciences appoints Jeremy Bender, Ph.D., M.B.A., to its Board of Directors. Bender, a biotech leader with experience in advancing therapies and commercialization, joins as the company prepares for potential regulatory approval of bel-sar for early choroidal melanoma. Aura aims to develop precision therapies preserving organ function, with bel-sar in late-stage development. Bender previously led Day One Biopharmaceuticals through its $2.5 b...
07-08 11:01
Mereo BioPharma Shareholders Approve All AGM Resolutions
Mereo Biopharma Group Plc ( ($MREO) ) has shared an update. On May 14, 2026, Me...
05-14 22:49
Mereo BioPharma Group Q1 EPS $(0.01), Inline
Mereo BioPharma Group (NASDAQ:MREO) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.02) per share from the same period last year.
05-12 19:35
